drugset / Trial / NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Timeline
- Start
- 2022-08-11
- Primary completion
- 2027-12
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavrostobart | Monoclonal antibody | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Pemetrexed | Small molecule | — | — |